Navigation Links
Amicus Therapeutics Announces First Quarter 2011 Financial Results and Continued Progress of Development Programs
Date:5/4/2011

CRANBURY, N.J., May 4, 2011 /PRNewswire/ -- Amicus Therapeutics (Nasdaq: FOLD), a biopharmaceutical company at the forefront of developing therapies for rare diseases, today announced financial results for the first quarter ended March 31, 2011. The Company also highlighted recent and upcoming milestones, including an update on patient enrollment in the ongoing Phase 3 study of its lead program Amigal™ (migalastat HCl) for Fabry disease.

Development Pipeline Highlights

  • Enrollment in Phase 3 Amigal study (Study 011) is nearing completion and is expected to be fully enrolled in 2Q11 or 3Q11
  • Phase 2 Amigal extension study continues to provide encouraging safety and renal function data following up to four years of treatment
  • Patient dosing commenced in Phase 2 study of Amigal co-administered with enzyme replacement therapy (ERT) for Fabry disease
  • Moving forward with Phase 2 study of AT2220 (1-deoxynojirimycin HCI) co-administered with ERT for Pompe disease

  • Matthew R. Patterson, President and Acting Chief Executive Officer of Amicus Therapeutics said, "We continue to make excellent progress across all parts of our business. Our Phase 3 study of Amigal for Fabry disease remains our top priority and we are close to enrolling the final patient. We are also excited to have dosed our first patient in a Phase 2 study evaluating pharmacological chaperones co-administered with ERT. We see this approach as an important extension of our science and a validation of the broader therapeutic potential of our pharmacological chaperone technology. Amicus is in a position of strategic and financial strength due to the positive momentum of our development programs and the successful collaboration with our partner, GSK Rare Diseases. Our team is focused on the achievement of multiple key milestones during 2011."

    First Qua
    '/>"/>

    SOURCE Amicus Therapeutics
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related medicine technology :

    1. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
    2. Amicus Therapeutics Announces Plans to Present Phase 1 Data for AT2220 for Pompe Disease
    3. Amicus Therapeutics Announces Positive Results From Two Phase 1 Clinical Studies of AT2220 for Pompe Disease
    4. Amicus Therapeutics to Present at the 26th Annual JPMorgan Healthcare Conference
    5. Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220
    6. Amicus Therapeutics Begins Phase 2 Clinical Trial of AT2220 in Pompe Disease
    7. Amicus Therapeutics Announces Successful Completion of End of Phase 2 Meeting With FDA for Amigal in Fabry Disease
    8. Amicus Therapeutics Announces Second Quarter 2008 Financial Results
    9. Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009
    10. Amicus Therapeutics Suspends Enrollment for Phase 2 Clinical Trial of AT2220 for Pompe Disease
    11. Amicus Therapeutics Announces Issuance of New Plicera(TM) Composition of Matter Patent
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/29/2015)... Cogentix Medical, Inc. (NASDAQ: CGNT ), a global medical ... results for the first quarter of fiscal year 2016, which ... August 10, 2015. The Company will host ... Monday, August 10, 2015 at 4:30 p.m. Eastern Time (3:30 ... Executive Officer, and Brett Reynolds , Chief Financial Officer, ...
    (Date:7/29/2015)... CITY, Calif. , July 29, 2015 /PRNewswire/ ... specialty pharmaceutical company focused on the development and ... acute and breakthrough pain, today announced that it ... close on Monday, Aug 3rd, 2015. AcelRx management ... p.m. Eastern Time (1:30 p.m. Pacific Time) on ...
    (Date:7/29/2015)... July 29, 2015  Efforts to improve working capital ... pharmaceutical firms in North America ... that an effective working capital management will ease the ... cliffs. Big pharma companies expect to invest in optimizing ... - http://photos.prnewswire.com/prnh/20150724/241957LOGO Analysis from ...
    Breaking Medicine Technology:Cogentix Medical to Announce First Quarter Fiscal 2016 Results on August 10, 2015 2AcelRx Pharmaceuticals to Hold Business Update and Second Quarter Financial Results Conference Call and Webcast on Monday, Aug. 3rd, 2015. 2AcelRx Pharmaceuticals to Hold Business Update and Second Quarter Financial Results Conference Call and Webcast on Monday, Aug. 3rd, 2015. 3AcelRx Pharmaceuticals to Hold Business Update and Second Quarter Financial Results Conference Call and Webcast on Monday, Aug. 3rd, 2015. 4Working Capital Management Seizes Priority in North American and European Pharma Industry 2Working Capital Management Seizes Priority in North American and European Pharma Industry 3Working Capital Management Seizes Priority in North American and European Pharma Industry 4
    ... Aug. 18, 2011 Insource Spend Management Group, ... services, announced it has hit a milestone of ... clients.  Many Fortune 500 clients have individually saved ... of software, analytics and expert negotiation. Shippers across ...
    ... Chief Financial Officer of Chembio Diagnostics, Inc. (OTCQB: CEMI) (OTC.BB: ... is among the recipients of the "2011 CFO of the ... LIBN ).  A total of 27 CFOs were awarded the ... of two CFOs of a public company with revenue under ...
    Cached Medicine Technology:Insource Saves Clients Over $1 Billion on Parcel Shipping 2Chembio Diagnostics' CFO Richard J. Larkin Among the Recipients of "2011 CFO of the Year" Award from Long Island Business News 2Chembio Diagnostics' CFO Richard J. Larkin Among the Recipients of "2011 CFO of the Year" Award from Long Island Business News 3
    (Date:7/29/2015)... ... 2015 , ... According to The Spirits Business on July 16th, ... for stimulating and perpetuating alcohol use disorders. Humans have the same gene, which is ... academy of Sciences, and has given researchers inklings to explore Rsu1 in humans to ...
    (Date:7/29/2015)... ... July 29, 2015 , ... CrossFit 269, offering ... July to Kalamazoo Strength & Conditioning. , The name change coincides with the ... of our training center over the past three years,” according to Jack Kelly, ...
    (Date:7/29/2015)... ... July 29, 2015 , ... For the second year in a ... the list of the 50 fastest growing companies in Jacksonville. This annual list is ... On July 16th, a team of Vast Bridges staffers were on hand to receive ...
    (Date:7/29/2015)... ... July 29, 2015 , ... CanAm Enterprises, LLC (“CanAm”) ... over the past month! I-829 approvals have been granted to investors in four different ... the Kimpton Lafayette Hotel project in Philadelphia, and the Valley Forge Convention Center project ...
    (Date:7/29/2015)... ... ... A June 10, 2015 article from the News-Press, entitled " It's Never ... regular skin cancer screenings from an early age. Skin cancer can strike at any ... skin cancer is rarely fatal; however, if left alone for too long, the fatality ...
    Breaking Medicine News(10 mins):Health News:Study Reveals Potential for Gene Manipulation to Stop Alcohol Addiction 2Health News:Study Reveals Potential for Gene Manipulation to Stop Alcohol Addiction 3Health News:Kalamazoo’s CrossFit 269 Changes Name, Opens New Website 2Health News:Kalamazoo’s CrossFit 269 Changes Name, Opens New Website 3Health News:Kalamazoo’s CrossFit 269 Changes Name, Opens New Website 4Health News:Vast Bridges Continues Its Swift Growth 2Health News:More Than 60 New I-829 Approvals in Less Than 30 days for CanAm 2Health News:More Than 60 New I-829 Approvals in Less Than 30 days for CanAm 3Health News:Get Checked for Skin Cancer Early and Often 2Health News:Get Checked for Skin Cancer Early and Often 3
    ... of women worrying about cancer may be experiencing sleep ... a research abstract that will be presented by Amita ... Annual Meeting of the Associated Professional Sleep Societies (APSS). ... Center at SUNY Downstate Medical Center and Long Island ...
    ... WESTCHESTER, Ill. Morningness is a predictor of better ... will be presented on Monday at SLEEP 2008, the ... (APSS). , The study, authored by Kendry Clay, of ... students who were enrolled in psychology classes. The ...
    ... , - ,Everyone Living in Dubai Will Have Access to ... - DHA responsible for strategy and policy, health regulation, ... owned public corporation to take over responsibility for ... body responsible for all health service professionals and ...
    ... cancer nurse will tell Teenage Cancer Trust,s Fifth International ... (Monday) how a young man waited for ten months ... lymphoma, after he was delayed by the referral pathway ... and young adult (TYA) Nurse Consultant at the Teenage ...
    ... study says , , SUNDAY, June 8 (HealthDay News) -- Adding ... the procedure may help hold it together better in the ... report that gradually adding parallel pressure -- as opposed to ... a graft helps then bind to the surfaces of the ...
    ... Compassionate Children gives cancer, survivor the ... college, BOSTON, June 7 Carolyn,s Compassionate,Children ... survivor Leanna,Elizalde with a $2,500 Survivorship Award after ... ceremony Saturday. Alex Oden, 20, a,two-time brain cancer ...
    Cached Medicine News:Health News:Women worrying about cancer are more likely to experience sleep disturbances 2Health News:Morningness a predictor of better grades in college 2Health News:Dubai Health Authority Unveils Healthcare for All 2Health News:Dubai Health Authority Unveils Healthcare for All 3Health News:Dubai Health Authority Unveils Healthcare for All 4Health News:Dubai Health Authority Unveils Healthcare for All 5Health News:Dubai Health Authority Unveils Healthcare for All 6Health News:Dubai Health Authority Unveils Healthcare for All 7Health News:Dubai Health Authority Unveils Healthcare for All 8Health News:Young patient waited ten months before being diagnosed with cancer 2Health News:Young patient waited ten months before being diagnosed with cancer 3Health News:Applying Parallel Pressure Improves Vascular Grafting 2Health News:Nonprofit Organization Dedicated to Helping Young Adult Cancer Survivors Raises $4500 for Leanna Elizalde 2
    This modular benchtop fume hood ventilates and purifies chemical fumes, allowing safe indoor release of exhaust. Bonded charcoal filters remove most organic contaminants. Options include final HEPA f...
    ... This fume hood is the ... but includes a flat internal ... the shell. The baffle slopes ... air flow to sweep the ...
    This fume hood features a one-piece shell molded of polyethylene with a clear acrylic panel that slides on inside tracks. It can be set in an open, closed or intermediate position....
    These handy dispensers save space and organize gloves in labs and next to hand washers. Clear acrylic. Many other sizes and custom configurations available....
    Medicine Products: